OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

The last trade today was a 'buy' of 500,000.
I look foward to seeing some more similar
size 'buys' over the next few days.

Panicking over the drop in the sp today?
Me nah! and nor is that investor by the
looks of things.

All the Best.

Apologies for this but I thought that I would post an update from DD on ADV as he had the gumption to actually find out a bit more:

DoobyDave - 2 Mar'05 - 14:19 - 4208 of 4280


With regard to my earlier post 4138 concerning the disease staging of the Trovax colorectal trial patients, I rang up the company a few minutes ago to clarify matters.

By way of reminder, five year survival rates by stage quoted by the Royal College of Surgeons are

Dukes' A - 85%
Dukes' B - 67%
Dukes' C - 37% (combines C1 and C2 stages)
Dukes' D (sometimes referred to as stage 4) - no figure quoted but approximates to zero over 5 years.

It turns out that the trial patients all had Duke's D (Stage 4) disease, with liver or other solid organ metastases (secondaries). The outlook for this group of patients is normally assured death within a year, often within a few weeks (there is huge variability).

Hence, these results ARE truly excellent, despite it being too early to be banking on long term survival.

Please note there is now a detailed presentation on the Oxford Biomedica website, Please especially note slide 10, which compares the chemotherapy agent alone to chemo plus Trovax. Combination with either agent increases clinical response rate by 50%. It also beats all other immunotherapy trials to date.

The other slide of major interest is slide 15, on anticipated newsflow.

The company confirms that there remains a possibility that further Trovax doses may further enhance survival, but this is purely speculative.
DD

[deleted - my mistake]

20.75p Down another 4.6%

If it goes under 20p then I'll increase my stake again.

Oxford Biomedica PLC
04 March 2005


FOR IMMEDIATE RELEASE 4 MARCH 2005

OXFORD BIOMEDICA ANNOUNCES BOARD APPOINTMENT



Oxford, UK - 4 March 2005: Oxford BioMedica (LSE:OXB.L), the leading gene
therapy company, today announces that Nick Woolf has been promoted to the Board
as an executive director. He will maintain his title of Senior Vice President
for Corporate Strategy. His primary responsibilities include corporate finance,
M&A evaluation and corporate communications as well as an important role,
jointly with Peter Nolan, in business development and deal negotiation.



Prior to joining Oxford BioMedica in 2002, Nick spent eight years as a top-rated
biotechnology and pharmaceutical analyst. Nick has been involved in all aspects
of company financing, ranging from IPOs to major corporate deals. He served as
Director and Head of European Biotechnology Research at ABN AMRO, and was
previously with Robertson Stephens International, Nomura and SBC Warburg. Nick
holds an MA from Oxford University in Chemistry.



Commenting on the Board appointment, Professor Alan Kingsman, Chief Executive of
Oxford BioMedica, said: 'Nick has contributed at a very high level to all
corporate activities and has been instrumental in raising the Company's profile
in the industry and the investment community. We are delighted to welcome him to
the Board.'



-Ends-

L2 anyone? TIA.

Bought a few more again this morning.

A moderate amount this time because there may be a slightly better opportunity soon.

Seems to be some more interest in this 1 today, I wonder why?

RNS Number:7109J
Oxford Biomedica PLC
14 March 2005


FOR IMMEDIATE RELEASE 14 MARCH 2005


OXFORD BIOMEDICA DEMONSTRATES THAT ITS LENTIVECTOR(R) TECHNOLOGY IS THE SYSTEM
OF CHOICE FOR RNAI APPLICATIONS


Oxford, UK - 14 March 2005: Oxford BioMedica (LSE:OXB.L), the leading gene
therapy company, announced today the publication, in the journal Nature
Medicine, of a paper demonstrating efficacy of the Company's LentiVector
technology in an animal model of inherited (familial) amyotrophic lateral
sclerosis (ALS) or motor neuron disease. The paper describes the delivery, by
the LentiVector technology, of a specific RNAi molecule that shuts down the gene
that causes the disease.


Familial ALS is caused by a series of mutations in a gene called SOD1. The
disease represents about 2% of the total ALS cases. These mutations cause the
SOD1 gene to acquire a new function that destroys motor neurons. The neurons die
and the patient loses muscle control in a similar way to the more common
acquired ALS or Lou Gehrig's disease. Patients generally die from respiratory
failure because they are unable to control their diaphragm muscle. Switching off
the gene stops the development of the disease but the challenge so far has been
to achieve that goal.


RNAi is a new technology that uses small RNA molecules to switch off any gene of
choice. It has been adopted widely by the pharmaceutical industry as a means of
identifying genes with a causative relationship to specific diseases. The
Company's LentiVector technology is perfectly suited to deliver these molecules
and this is what has been reported in the Nature Medicine paper. A LentiVector
has been used to deliver a highly specific RNAi molecule to a selection of motor
neurons in a mouse that has the mutated SOD1 gene. The data show that delivery
was very efficient and there was a 100% extension of the time to onset of the
disease as well as a 70% increase in survival.


Commenting on the results the Company's CEO, Prof. Alan Kingsman, said: "These
data show that our LentiVector technology is the system of choice for the
genetic delivery of RNAi molecules. This is a particularly powerful illustration
of the point and is assisting us with our ongoing out-licensing of the
LentiVector technology for drug discovery and transgenic applications. We have
already completed four such deals and we have five further term sheets under
discussion."


From a rare visit to the other side, where there is some optimism over the last sentence above. Cheers, Madison.

here we go again, trading volumes suddenly risen, mostly Buys. Back to 28? The news of course is excellent but we all know that unless they announce a definite cure for all cancers, then news doesn't budge Oxb. No, it's prob more takeover speculation. The co is worth a lot more by the mth as more data is released.

Hi guys,

Perhaps it's this:

http://www.oxfordbiomedica.co.uk/news/2005-ob-08.htm

That's been causing some speculative interest in the last couple of days.

I shall try (if at all possible) to be tuned in to listen to the webcast.

Cheers,

mcp2.

This is from the press summary from todays Express:

SHARE WHISPER: OXFORD BIOMEDICA (talk of a potential partnership deal with Johnson & Johnson, which could be mulling a takeover)

Also just listened to the webcast and all that talk of studies takes me back to my uni days. The main subjects covered were the various products they are developing. The work they are doing does sound impressive to me and seems to be coming along nicely. Not sure how this should affect the share price but everything appears to be ticking along nicely.

Thanks nice research - reckon we are bound for "Route 66"

the webcast will be on their site for the next month or so if anyone wants to have a listen. the speech was about half an hour long.

Thanks tbrooking66

How nice OXB UP yet again!

I seem to have timed it right again, on Monday.

Results on Mon 21st March - Licence announcement to coincide would be nice and IMHO expected.

lifted from press round-up of today (from the independant):

*Hopes of cancer treatment licensing deal at Oxford Biomedica (LSE: OXB.L - news) .

Thanks tbrooking66

It started to drop so I lightened up my holding a bit.

I think we may have peaked again for the time being.

Results Monday are unlikely to be great but that may be cancelled out if a licencing deal is announced on the same day.

I've set an automatic stop loss for a chunk of my holding.

Oxford Biomedica PLC
21 March 2005


FOR IMMEDIATE RELEASE 21 MARCH 2005




OXFORD BIOMEDICA PLC

PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2004


Oxford, UK - 21 March 2005: Oxford BioMedica (LSE: OXB), the leading gene
therapy company, today announces its preliminary results for the year ended 31
December 2004. Highlights:


Oncology

TroVax: Phase II results in colorectal cancer alongside chemotherapy
exceeded expectations, demonstrating immune responses in all patients and
clinical benefit in the majority. Announced on 2 March 2005

TroVax: Phase I/II follow-up analysis showed a highly significant
correlation between immune responses and time to disease progression

TroVax: Phase II trial in renal cell carcinoma commenced in the United
States

TroVax: commercial manufacture established with over 22,000 doses
produced

TroVax: plans for registration trials to be discussed with the FDA
imminently

Anti-5T4 targeted antibody: Wyeth completed its preclinical evaluation
and clinical trials are under consideration

MetXia: Phase I rolling to Phase II trial in pancreatic cancer underway



Neurotherapy

ProSavin: preclinical results showed almost complete recovery in movement
behaviour in Parkinson's disease

ProSavin: regulatory discussions ongoing prior to formal submissions for
clinical trials

MoNuDin: preclinical results demonstrated a highly significant increase
in life expectancy in ALS, published in Nature

SMN-1G: preclinical results showed a statistically significant
improvement in survival in spinal muscular atrophy, published in the
Journal of Clinical Investigation

Innurex: preclinical results showed restoration of limb function in
avulsion or stretch injury



Technology licensing

Four technology licensing agreements signed during 2004 and another since
the year end, generating sustainable revenue

Merck & Co and Biogen Idec licensed the LentiVector technology for
research use

Viragen licensed the LentiVector technology for biomanufacturing using
avian transgenics

MolMed licensed the retroviral ex vivo gene delivery technology for
therapeutic applications



Financial

Revenue for the year ended 31 December 2004 increased 34 per cent to 0.5
million (2003: 0.4 million) reflecting growing income from licensing

Loss before tax and exceptional items for the year reduced to 11.1
million (2003: 12.7 million)

Operating expenses for the year were essentially unchanged at 13.5
million (2003: 13.7 million)

Cash and short term investments at 31 December 2004 of 22.4 million
(2003: 31.8 million)

Cash resources sufficient to support development activities into 2007,
before taking account of new licensing agreements



Board appointment

Nick Woolf, Senior Vice President for Corporate Strategy, appointed to
the Board as an executive director on 3 March 2005


Commenting on the results, Oxford BioMedica's Chief executive, Professor Alan
Kingsman said: 'We have made good progress during 2004 in both product
development and licensing. In particular, the recent successful Phase II results
with TroVax have confirmed the potential for our lead product. The value of our
technology platforms is also becoming evident. In 2004 and since the year end,
we have secured five technology licensing deals, which are generating growing
and sustainable revenue. More deals on technology and products are expected. At
the same time, we are moving TroVax towards registration trials and taking the
lead neurotherapy products towards clinical development. With our solid cash
position, we are well placed to deliver on our objectives. We look forward to
the coming year as our products and technologies advance towards
commercialisation.'


-Ends-